Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation.

The understanding that asthma pathophysiology includes an inflammatory component has spurred the more aggressive use of anti-inflammatory therapies and created a need for effective tools to measure inflammation. Biomarkers of airway inflammation proposed are obtained by methods that are direct but highly invasive (bronchial biopsy, bronchoalveolar lavage), moderately direct, and less invasive (indirect sputum, exhaled air, breath condensate) or indirect and least invasive (blood, urine). Several studies described in this review have implicated the cysteinyl leukotrienes (CysLTs) as inflammatory mediators in a wide range of diseases, implying that their biological activities reach far beyond acute bronchoconstriction, the activity traditionally ascribed to them. The validity of examining sputum for "biomarkers" has improved the understanding of asthma pathophysiology, optimization of asthma treatment and management, and investigation of the relation between CysLTs and airway inflammation in asthma. Nitric oxide is also a surrogate marker of asthma and reflects airway inflammation. The anti-inflammatory effects of the leukotriene receptor antagonists and the markers of their activity continue to grow.

[1]  I. Momas,et al.  Clinical significance of bronchoalveolar eosinophils in childhood asthma. , 2002, The Journal of allergy and clinical immunology.

[2]  T. Haahtela,et al.  Cell specific markers for eosinophils and neutrophils in sputum and bronchoalveolar lavage fluid of patients with respiratory conditions and healthy subjects , 2002, Thorax.

[3]  M. Peters-Golden,et al.  Leptin-Deficient Mice Exhibit Impaired Host Defense in Gram-Negative Pneumonia1 , 2002, The Journal of Immunology.

[4]  I. Adcock,et al.  Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. , 2001, American journal of respiratory and critical care medicine.

[5]  P. O'Byrne,et al.  Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. , 2001, American journal of respiratory and critical care medicine.

[6]  R. Hancox,et al.  The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. , 2001, American journal of respiratory and critical care medicine.

[7]  P. Barnes,et al.  Exhaled markers of pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[8]  B. Lipworth,et al.  A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[9]  H. Bisgaard,et al.  FeNO measured at fixed exhalation flow rate during controlled tidal breathing in children from the age of 2 yr. , 2001, American journal of respiratory and critical care medicine.

[10]  H. Bisgaard.  Leukotriene modifiers in pediatric asthma management. , 2001, Pediatrics.

[11]  C. Jenkins,et al.  Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. , 2001, American journal of respiratory and critical care medicine.

[12]  E. Silverman,et al.  Exhaled nitric oxide in patients with asthma: association with NOS1 genotype. , 2000, American journal of respiratory and critical care medicine.

[13]  E. Israel,et al.  Exhaled nitric oxide following leukotriene E(4) and methacholine inhalation in patients with asthma. , 2000, American journal of respiratory and critical care medicine.

[14]  I. Sayers,et al.  Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast , 2000, Thorax.

[15]  M. Sanak,et al.  Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. , 2000, American journal of respiratory cell and molecular biology.

[16]  B. Lipworth,et al.  Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype. , 2000, The American journal of medicine.

[17]  H. Magnussen,et al.  Update on sputum methodology. , 2000, The European respiratory journal.

[18]  Nakagawa,et al.  Effect of pranlukast on bronchial inflammation in patients with asthma , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  J. Drazen,et al.  5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. , 2000, The Journal of allergy and clinical immunology.

[20]  E. Silverman,et al.  A neuronal NO synthase (NOS1) gene polymorphism is associated with asthma. , 2000, Biochemical and biophysical research communications.

[21]  R. Djukanović.  Induced sputum--a tool with great potential but not without problems. , 2000, The Journal of allergy and clinical immunology.

[22]  P. Barnes,et al.  Automated quantitation of circulating neutrophil and eosinophil activation in asthmatic patients , 2000, Thorax.

[23]  L. Bjermer,et al.  Combined use of exhaled nitric oxide and airway hyperresponsiveness in characterizing asthma in a large population survey. , 2000, The European respiratory journal.

[24]  A. Wells,et al.  Increased nitric oxide production in the respiratory tract in asymptomatic pacific islanders: an association with skin prick reactivity to house dust mite. , 2000, The Journal of allergy and clinical immunology.

[25]  I. Pavord,et al.  Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. , 2000, American journal of respiratory and critical care medicine.

[26]  S. Stick,et al.  Raised exhaled nitric oxide in healthy children is associated with domestic formaldehyde levels. , 2000, American journal of respiratory and critical care medicine.

[27]  E. Bleecker,et al.  Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. , 2000, American journal of respiratory and critical care medicine.

[28]  S. Permutt,et al.  Airway nitric oxide diffusion in asthma: Role in pulmonary function and bronchial responsiveness. , 2000, American journal of respiratory and critical care medicine.

[29]  S. Holgate,et al.  Antileukotriene therapy. Future directions. , 2000, American journal of respiratory and critical care medicine.

[30]  H. Hoogsteden,et al.  Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness. , 2000, American journal of respiratory and critical care medicine.

[31]  C. White,et al.  Exhaled nitric oxide before and after montelukast sodium therapy in school‐age children with chronic asthma: A preliminary study , 1999, Pediatric pulmonology.

[32]  R. Hataishi,et al.  Decreased exhaled nitric oxide in mild persistent asthma patients treated with a leukotriene receptor antagonist, pranlukast. , 1999, The Japanese journal of physiology.

[33]  I. Pavord,et al.  Induced sputum eicosanoid concentrations in asthma. , 1999, American journal of respiratory and critical care medicine.

[34]  Nakahara,et al.  Effects of ONO‐1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[35]  P. Sterk,et al.  E V ect of oral L -arginine on airway hyperresponsiveness to histamine in asthma , 1999 .

[36]  C. Roussos,et al.  Influence of atopy on exhaled nitric oxide in patients with stable asthma and rhinitis. , 1999, The European respiratory journal.

[37]  H. Bisgaard,et al.  NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. , 1999, American journal of respiratory and critical care medicine.

[38]  L. Boulet,et al.  Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. , 1999, The European respiratory journal.

[39]  F. Hargreave,et al.  Nonasthmatic chronic cough: No effect of treatment with an inhaled corticosteroid in patients without sputum eosinophilia. , 1999, Canadian respiratory journal.

[40]  I. Pavord,et al.  Non-eosinophilic cor ticosteroid unresponsive asthma , 1999, The Lancet.

[41]  L. Gortner,et al.  Childhood asthma: exhaled nitric oxide in relation to clinical symptoms. , 1999, The European respiratory journal.

[42]  J. Drazen,et al.  Contribution of Nitric Oxide Synthases 1, 2, and 3 to Airway Hyperresponsiveness and Inflammation in a Murine Model of Asthma , 1999, The Journal of experimental medicine.

[43]  G. Rossi,et al.  Orally exhaled nitric oxide levels are related to the degree of blood eosinophilia in atopic children with mild-intermittent asthma. , 1999, The European respiratory journal.

[44]  E. Israel,et al.  Correction: Treatment of Asthma with Drugs Modifying the Leukotriene Pathway. , 1999, The New England journal of medicine.

[45]  A. Zwinderman,et al.  The effect of montelukast (MK‐0476), a cysteinyl leukotriene receptor antagonist, on allergen‐induced airway responses and sputum cell counts in asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[46]  E. Baraldi,et al.  Effect of natural grass pollen exposure on exhaled nitric oxide in asthmatic children. , 1999, American journal of respiratory and critical care medicine.

[47]  A. Boner,et al.  Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children. , 1999, The European respiratory journal.

[48]  I. Pavord,et al.  Prednisone-dependent asthma: inflammatory indices in induced sputum. , 1999, The European respiratory journal.

[49]  K. Chung,et al.  Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. , 1999, American journal of respiratory and critical care medicine.

[50]  J. Bernstein,et al.  Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. , 1999, JAMA.

[51]  S. Durham,et al.  Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids , 1998, Thorax.

[52]  F. Hargreave,et al.  Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. , 1998, American journal of respiratory and critical care medicine.

[53]  M. Kumlin,et al.  Urinary excretion of inflammatory mediators during allergen‐induced early and late phase asthmatic reactions , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[54]  P. Gibson.  Use of induced sputum to examine airway inflammation in childhood asthma. , 1998, The Journal of allergy and clinical immunology.

[55]  A. Adisesh,et al.  Relationship between exhaled nitric oxide and childhood asthma. , 1998, American journal of respiratory and critical care medicine.

[56]  Teruo Sakamoto,et al.  Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma , 1998, Thorax.

[57]  M. Sears,et al.  Potential masking effects of salmeterol on airway inflammation in asthma. , 1998, American journal of respiratory and critical care medicine.

[58]  P. Barnes,et al.  Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  F. Hargreave,et al.  Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. , 1998, Canadian respiratory journal.

[60]  R. Dockhorn,et al.  Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. , 1998, Archives of internal medicine.

[61]  J. Bernstein,et al.  Montelukast for Chronic Asthma in 6- to 14-Year-Old Children A Randomized, Double-blind Trial , 1998 .

[62]  P. O'Byrne,et al.  Induced sputum, bronchoalveolar lavage and blood from mild asthmatics: inflammatory cells, lymphocyte subsets and soluble markers compared. , 1998, European Respiratory Journal.

[63]  G. Verleden,et al.  Exhaled nitric oxide correlates with airway hyperresponsiveness in steroid-naive patients with mild asthma. , 1998, American journal of respiratory and critical care medicine.

[64]  K. Chung,et al.  Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. , 1998, Thorax.

[65]  E. Bleecker,et al.  Relationship between airway obstruction and respiratory symptoms in adult asthmatics. , 1998, Chest.

[66]  J. Westcott,et al.  Leukotriene Receptors: Incompletely Defined Targets for Treatment of Asthma and Inflammation , 1998 .

[67]  M. Sanak,et al.  Leukotriene C 4 synthase promoter polymorphism and risk of aspirin-induced asthma , 1997, The Lancet.

[68]  E. Baraldi,et al.  Corticosteroids decrease exhaled nitric oxide in children with acute asthma. , 1997, The Journal of pediatrics.

[69]  I. Pavord,et al.  The use of induced sputum to investigate airway inflammation. , 1997, Thorax.

[70]  F. Hargreave,et al.  Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. , 1997, American journal of respiratory and critical care medicine.

[71]  M. Kondo,et al.  Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. , 1997, American journal of respiratory and critical care medicine.

[72]  F. Hargreave,et al.  Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. , 1997, The Journal of allergy and clinical immunology.

[73]  H. Schmidt,et al.  No .NO from NO synthase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[74]  M. Jordana,et al.  Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. , 1996, American journal of respiratory and critical care medicine.

[75]  G. Bonsignore,et al.  Urinary leukotriene E4 in the assessment of nocturnal asthma. , 1996, The Journal of allergy and clinical immunology.

[76]  F. Hargreave,et al.  Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. , 1996, The European respiratory journal.

[77]  E. Israel,et al.  Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. , 1995, The Journal of allergy and clinical immunology.

[78]  M. Sears,et al.  Exacerbations of asthma without sputum eosinophilia. , 1995, Thorax.

[79]  D. Yates,et al.  Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. , 1995, American journal of respiratory and critical care medicine.

[80]  S. Erzurum,et al.  Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[81]  P. Barnes,et al.  Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide. , 1995, American journal of respiratory and critical care medicine.

[82]  T. Hökfelt,et al.  High nitric oxide production in human paranasal sinuses , 1995, Nature Medicine.

[83]  D. Yates,et al.  Exhaled nitric oxide is increased in asthma. , 1995, Chest.

[84]  P. Gibson,et al.  Chronic cough with eosinophilic bronchitis: examination for variable airflow obstruction and response to corticosteroid , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[85]  L. Wu,et al.  Endothelial nitric oxide synthase is expressed in cultured human bronchiolar epithelium. , 1994, The Journal of clinical investigation.

[86]  J. Polak,et al.  Expression of inducible nitric oxide in human lung epithelial cells. , 1994, Biochemical and biophysical research communications.

[87]  C. Nathan,et al.  Regulation of biosynthesis of nitric oxide. , 1994, The Journal of biological chemistry.

[88]  J. Oates,et al.  Effect of oral prednisone on airway inflammatory mediators in atopic asthma. , 1994, American journal of respiratory and critical care medicine.

[89]  D. Woodward,et al.  Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro , 1994, Journal of leukocyte biology.

[90]  P. Howarth,et al.  Induction of nitric oxide synthase in asthma , 1993, The Lancet.

[91]  N. Wiklund,et al.  Endogenous nitric oxide in single exhalations and the change during exercise. , 1993, The American review of respiratory disease.

[92]  E. Weitzberg,et al.  Increased amount of nitric oxide in exhaled air of asthmatics. , 1993, The European respiratory journal.

[93]  C. Dollery,et al.  Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. , 1993, The American review of respiratory disease.

[94]  T. Haahtela,et al.  Leukotriene E4 and granulocytic infiltration into asthmatic airways , 1993, The Lancet.

[95]  P. O'Byrne,et al.  Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. , 1992, The American review of respiratory disease.

[96]  S. Dahlén,et al.  Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. , 1992, The American review of respiratory disease.

[97]  G. Guyatt,et al.  A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[98]  J. Denburg,et al.  Use of induced sputum cell counts to investigate airway inflammation in asthma. , 1992, Thorax.

[99]  S Moncada,et al.  Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. , 1991, Biochemical and biophysical research communications.

[100]  P. Howarth,et al.  The safety aspects of fiberoptic bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in asthma. , 1991, The American review of respiratory disease.

[101]  C. Dollery,et al.  URINARY LEUKOTRIENE E4 AFTER ANTIGEN CHALLENGE AND IN ACUTE ASTHMA AND ALLERGIC RHINITIS , 1989, The Lancet.

[102]  H. Bisgaard.  Vascular effects of leukotriene D4 in human skin. , 1987, The Journal of investigative dermatology.

[103]  H. Bisgaard,et al.  Leukotriene- and histamine-induced increases in vascular permeability and interstitial transport in the skin. , 1985, The Journal of investigative dermatology.

[104]  W. Martin,et al.  Letter: Jaundice associated with norethisterone-acetate treatment of breast cancer. , 1975, Lancet.

[105]  W. A. Newman Dorland,et al.  Dorland's Illustrated Medical Dictionary , 1974 .